CN1289619A - Eye drops and its preparing process - Google Patents
Eye drops and its preparing process Download PDFInfo
- Publication number
- CN1289619A CN1289619A CN 99117113 CN99117113A CN1289619A CN 1289619 A CN1289619 A CN 1289619A CN 99117113 CN99117113 CN 99117113 CN 99117113 A CN99117113 A CN 99117113A CN 1289619 A CN1289619 A CN 1289619A
- Authority
- CN
- China
- Prior art keywords
- growth factor
- eye drop
- fibroblast growth
- injection
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The eye drops contains 0.5-20 micro grams/ml solutions of alkaline and/or acidic fibroblast growth factors and/or epidermal growth factor. Its advantages include no irritation and multiple functions of moistening eye, improving vision, relieving eye fatigue and repairing eye damage.
Description
The present invention relates to a kind of eye drop and preparation method thereof.
Forming by antibiotics, chloromycetin etc. usually of existing eye drop, as disclosed eye drop among the Chinese patent CN86101743 and the disclosed eye drop of Chinese patent application CN94107398, these eye drop have antibiotic, antiinflammation, but to promoting corneal injury, as because to wear the active reparation of corneal injury that contact lens causes and other ophthalmic injuries powerless.
The object of the present invention is to provide a kind of corneal damage and other ophthalmic injuries to have and promote its initiatively eye drop of repair.
Another object of the present invention is to provide a kind of method for preparing above-mentioned eye drop.
Eye drop of the present invention, contain 0.5～20ug/ml basic fibroblast growth factor, acid fibroblast growth factor, a kind of in the epidermal growth factor, two or three aqueous solution, wherein can also contain 0.1 ten thousand units～1,000,000 units/ml α 2a type interferon or α 1b type interferon, can also contain percentage by weight in addition is the antibacterial of conventional amount used in 0.01%～0.3% hyaluronate sodium and/or 0.02%～2% albumin and/or 0.1%～1% sodium chloride and/or 0.02%～10% mannitol and/or the eye drop, basic fibroblast growth factor wherein, acid fibroblast growth factor, epidermal growth factor, albumin and mannitol are lyophilized powder, and antibacterial is a sodium benzoate, oxybenzene second fat, hydrochloric acid Chlorhexidine or glucose Chlorhexidine.
The method for preparing eye drop of the present invention, form by following steps: (1) with in basic fibroblast growth factor, acid fibroblast growth factor, the epidermal growth factor a kind of, two or three and/or albumin and/or mannitol separately or mix the back and dissolve with water for injection, filter then, degerming, lyophilized powder is made in last lyophilization; (2) be dissolved in water for injection or with interferon and/or hyaluronate sodium and/or sodium chloride and/or antibacterial and make solvent in the water for injection.During use, lyophilized powder is poured in the solvent, mixing can use.The lyophilized powder of basic fibroblast growth factor and/or acid fibroblast growth factor and/or epidermal growth factor and/or albumin and/or mannitol and the solvent of water for injection and/or interferon and/or hyaluronate sodium and/or sodium chloride and/or antibacterial composition are placed respectively, can be prolonged the storage life of eye drop.
Basic fibroblast growth factor, acid fibroblast growth factor, epidermal growth factor lyophilized powder are the active substances of denier in the human body, having induction of vascular forms, microcirculation improvement promotes fibroblast, epithelial cell, sarcoplast, neurocyte and physiological actions such as osteocyte growth and reparation.Therefore eye drop of the present invention has loose ciliary muscle, anti-eye strain, and the function of preserving moisture and making eye bright, and have the function that promotes that corneal injury and other ophthalmic injuries are initiatively repaired.
Eye drop of the present invention is compared with existing eye drop, nonirritant not only, and having preserves moisture makes eye bright, the anti-eye strain function, and the active reparation of corneal damage and other ophthalmic injuries has extremely strong facilitation.
Embodiment 1
(1) the 7.5ug basic fibroblast growth factor is dissolved with 10ml water for injection, filter then, degerming, lyophilized powder is made in last lyophilization; (2) use 10ml water for injection as solvent; (3) lyophilized powder is dissolved in the solvent.
Embodiment 2
(1) the 100ug acid fibroblast growth factor is dissolved with 10ml water for injection, filter then, degerming, lyophilized powder is made in last lyophilization; (2) use 10ml water for injection as solvent; (3) lyophilized powder is dissolved in the solvent.
Embodiment 3
(1) the 200ug epidermal growth factor is dissolved with 10ml water for injection, filter then, degerming, lyophilized powder is made in last lyophilization; (2) use 10ml water for injection as solvent; (3) lyophilized powder is dissolved in the solvent.
Embodiment 4
(1) 5ug basic fibroblast growth factor, 5ug acid fibroblast growth factor and 0.1g albumin are dissolved with 10ml water for injection, filter then, degerming, lyophilized powder is made in last lyophilization; (2) the α 2a type interferon of 2.5 ten thousand units is dissolved in the 10ml water for injection makes solvent; (3) lyophilized powder is dissolved in the solvent.
Embodiment 5
(1) 40ug basic fibroblast growth factor, 40ug epidermal growth factor and 0.5g mannitol are dissolved with 10ml water for injection, filter then, degerming, lyophilized powder is made in last lyophilization; (2) α 1b type interferon, 0.015g hyaluronate sodium and the 0.09g sodium chloride of 4,000,000 units is dissolved in the 10ml water for injection makes solvent; (3) lyophilized powder is dissolved in the solvent.
Embodiment 6
(1) 75ug acid fibroblast growth factor, 75ug epidermal growth factor, 0.05g mannitol and 0.05g albumin are dissolved with 10ml water for injection, filter then, degerming, lyophilized powder is made in last lyophilization; (2) α 1b type interferon, 0.005g hyaluronate sodium, 0.09g sodium chloride and the liposoluble of 0.003g oxybenzene second of 9,000,000 units are made solvent in 10ml water for injection; (3) lyophilized powder is dissolved in the solvent.
Embodiment 7
(1) 15ug basic fibroblast growth factor, 10ug acid fibroblast growth factor, 25ug epidermal growth factor are dissolved with 10ml water for injection, filter then, degerming, lyophilized powder is made in last lyophilization; (2) the 0.01g sodium benzoate is dissolved in the 10ml water for injection makes solvent; (3) lyophilized powder is dissolved in the solvent.
The experiment of embodiment 8 eye irritations
Splash into the eye drop of embodiment 1 to 7 for the left eye of rabbit, right eye splashes into normal saline in contrast, administration in continuous ten days, and the scoring of record irritant reaction, its last integration is as shown in table 1.
Table 1 rabbit eye irritation experimental result
According to eye irritation evaluation criterion table, non-stimulated scope is 0～3.00, and the score value of above-mentioned experiment shows that eye drop of the present invention is to tame lagophthalmos nonirritant all in this scope.
Embodiment 9 repairs experiment
Eye drop treatment rabbit cornea with embodiment 1 to 7 penetrates logical wound the (concurrent keratitis, local vascular damage), positive control and negative control give chloromycetin collyrium and normal saline respectively, every day, eye drip was three times, administration eight days, with ophthalmology sem observation corneal healing degree and measure intraocular pressure, the result uses the corneal healing of embodiment 1 to 7 eye drop and capillary tube to repair speed all than matched group fast 2～3 days, shows that the eye drop of embodiment 1 to 7 has its effect of initiatively repairing of extremely strong promotion.
Claims (7)
1, a kind of eye drop contains a kind of, two or three aqueous solution in 0.5～20ug/ml basic fibroblast growth factor, acid fibroblast growth factor, the epidermal growth factor.
2, eye drop as claimed in claim 1 is characterized in that containing 0.1 ten thousand units～1,000,000 units/ml interferon.
3, eye drop as claimed in claim 2 is characterized in that interferon is α 2a type interferon or α 1b type interferon.
4, eye drop as claimed in claim 1 or 2 is characterized in that containing the antibacterial that percentage by weight is a conventional amount used in 0.01%～0.3% hyaluronate sodium and/or 0.02%～2% albumin and/or 0.1%～1% sodium chloride and/or 0.02%～10% mannitol and/or the eye drop.
5, eye drop as claimed in claim 4 is characterized in that basic fibroblast growth factor, acid fibroblast growth factor, epidermal growth factor, albumin and mannitol are lyophilized powder.
6, eye drop as claimed in claim 4 is characterized in that antibacterial is sodium benzoate, oxybenzene second fat, hydrochloric acid Chlorhexidine or glucose Chlorhexidine.
7, a kind of method for preparing the described eye drop of claim 4, form by following steps: (1) with in basic fibroblast growth factor, acid fibroblast growth factor, the epidermal growth factor a kind of, two or three and/or albumin and/or mannitol separately or mix the back and dissolve with water for injection, filter then, degerming, lyophilized powder is made in last lyophilization; (2) be dissolved in water for injection or with interferon and/or hyaluronate sodium and/or sodium chloride and/or antibacterial and make solvent in the water for injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 99117113 CN1289619A (en) | 1999-09-24 | 1999-09-24 | Eye drops and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 99117113 CN1289619A (en) | 1999-09-24 | 1999-09-24 | Eye drops and its preparing process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1289619A true CN1289619A (en) | 2001-04-04 |
Family
ID=5279759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 99117113 Pending CN1289619A (en) | 1999-09-24 | 1999-09-24 | Eye drops and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1289619A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101947309A (en) * | 2010-04-12 | 2011-01-19 | 南海朗肽制药有限公司 | Human basic fibroblast growth factor eye drops and preparation method thereof |
| CN102357243A (en) * | 2011-11-02 | 2012-02-22 | 珠海亿胜生物制药有限公司 | Recombinant cattle basic fibroblastic growth factor eye drops |
| CN102362856A (en) * | 2011-11-02 | 2012-02-29 | 珠海亿胜生物制药有限公司 | Recombinant bovine basic fibroblast grow factor external solution |
| CN104606666A (en) * | 2015-02-12 | 2015-05-13 | 珠海亿胜生物制药有限公司 | Recombinant bovine alkaline fibroblast growth factor eye drops |
-
1999
- 1999-09-24 CN CN 99117113 patent/CN1289619A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101947309A (en) * | 2010-04-12 | 2011-01-19 | 南海朗肽制药有限公司 | Human basic fibroblast growth factor eye drops and preparation method thereof |
| CN101947309B (en) * | 2010-04-12 | 2012-09-19 | 南海朗肽制药有限公司 | Human basic fibroblast growth factor eye drops and preparation method thereof |
| CN102357243A (en) * | 2011-11-02 | 2012-02-22 | 珠海亿胜生物制药有限公司 | Recombinant cattle basic fibroblastic growth factor eye drops |
| CN102362856A (en) * | 2011-11-02 | 2012-02-29 | 珠海亿胜生物制药有限公司 | Recombinant bovine basic fibroblast grow factor external solution |
| CN104606666A (en) * | 2015-02-12 | 2015-05-13 | 珠海亿胜生物制药有限公司 | Recombinant bovine alkaline fibroblast growth factor eye drops |
| CN104606666B (en) * | 2015-02-12 | 2016-03-23 | 珠海亿胜生物制药有限公司 | BFGF bovine basic fibroblast growth factor eye drop |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5427778A (en) | Gel formulations containing growth factors and acrylamide polymer | |
| US5457093A (en) | Gel formulations containing growth factors | |
| JP4551563B2 (en) | Method for producing hyaluronic acid gel and medical material | |
| US4819617A (en) | Viscoelastic material for ophthalmic surgery | |
| JPH068323B2 (en) | Hyaluronic acid pharmacologically active fraction, method for producing the same and pharmaceutical composition | |
| HU223880B1 (en) | Gel formulations containing growth factors | |
| US5103840A (en) | Viscoelastic collagen gel for ophthalmic surgery | |
| CA2161774C (en) | Synthetic viscoelastic material for ophthalmic applications | |
| CN113549227B (en) | Chemical crosslinking hydrogel and microsphere thereof, preparation method and application | |
| US8889175B2 (en) | Nanoparticulate in-situ gels as vitreous humor substitutes for ocular diseases | |
| US20060110459A1 (en) | Triple natural polymer viscoelastic composition | |
| JP2009515921A (en) | Pharmaceutical composition free of dexpantenol, calcium ions and phosphate, and the use of calcium chelators and ophthalmically compatible viscosity modifiers | |
| CN111407774B (en) | Ophthalmic composition and preparation method thereof | |
| KR20110127746A (en) | Injectable biomaterials | |
| ES2304913T3 (en) | REEPITELIALIZING PHARMACEUTICAL COMPOSITIONS CONTAINING XANTAN GUM. | |
| DE60006660T2 (en) | USE OF A PARTICULAR HYALURONIDAINE FOR THE REMOVAL OF HORN SKIN TISSUE, TURBIDITY AND TANNY | |
| Bernatchez et al. | Use of hyaluronic acid in ocular therapy | |
| US20180200340A1 (en) | Wound Treatment | |
| Aquavella et al. | Therapeutic applications of a collagen bandage lens: A preliminary report | |
| CN1289619A (en) | Eye drops and its preparing process | |
| CN106943590B (en) | Pharmaceutical composition containing NGF for treating corneal epithelial injury | |
| CN102038953B (en) | Composite for local anesthesia before ophthalmologic operation and preparation method and application thereof | |
| CN111001010A (en) | External eye operation flushing fluid and preparation method thereof | |
| JP2022517722A (en) | Hydrogel composition for the eye | |
| JP5461468B2 (en) | Method for producing hyaluronic acid gel and medical material containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |